Introduction {#s0005}
============

The development of cancers has recently been linked to a small subset of cells capable of reproducing the cancer cell population and forming tumors, designated as tumor-initiating or cancer stem cells (CSC) [@bb0005], [@bb0010]. In head and neck squamous cell carcinomas (HNSCC), cells with CSC-like phenotype and tumor forming properties have been identified in tumors and cell lines [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030]. Recently, HNSCC CSC were found to be enriched within the "side population" (SP) of cells excluding Hoechst dye 33342 by fluorescence activated cell sorter analysis [@bb0030], a phenotype also associated with export and resistance to chemotherapy. Such isolated SP cells, when compared to non-SP cells, differentially expressed stem cell gene markers *BMI-1* and *ABCG2* transporter, formed self-replicating spheroids *in vitro*, and initiated tumors, characteristic of CSCs. Genes encoding key stem cell factors that promote the developmental stem cell phenotype, including *Sox2*, *Oct4* and *Nanog*, are also increased within tumors and CSC in HNSCC [@bb0035]. Sox2, Oct4, and Nanog activation, target gene regulation, and the CSC phenotype are inducible, supporting their functional importance in HNSCC CSCs. However, the signal and transcription factors orchestrating expression of these genes and the CSC phenotype in HNSCC are incompletely understood.

Among possible candidates, CK2 (formerly casein kinase II) has emerged as a key signal serine/threonine kinase that modulates diverse proteins and target cascades to regulate cell fate and growth [@bb0040]. CK2 is dysregulated in most cancers examined, including HNSCC, where it is aberrantly expressed and activated [@bb0040], [@bb0045], [@bb0050]. CK2 is detected as a tetrameric complex comprised of catalytic α and/or α′ and regulatory β subunits in the cytoplasm that mediate cell signaling. Additionally, catalytic CK2α subunits have also been found to be localized to the nucleus and complexed with chromatin, suggesting a potential role for CK2α in regulating gene transcription and expression [@bb0050]. Supporting this possibility, we demonstrated that CK2α is a key mediator repressing expression and function of the critical transcription factor and tumor suppressor TP53, in a subset of HNSCC with wild type *TP53* genotype [@bb0055]. Knockdown of CK2 by siRNA, particularly CK2α, increased TP53 mRNA and protein expression, inducing TP53-mediated growth arrest and apoptosis *in vitro*, and inhibiting tumorigenesis of wtTP53 HNSCC xenografts *in vivo* [@bb0055]. Intriguingly, TP53 activated by ultraviolet light-induced DNA damage has also been previously implicated in terminating embryonic stem cell renewal, by suppressing *Nanog* transcription and expression [@bb0060]. Unfortunately, TP53 is directly mutated in the majority of epithelial malignancies, and \> 70% of HNSCC [@bb0065], compromising its potential to suppress CSC gene expression and tumorigenesis. However, the TP53 family also includes p63 and p73, which are implicated in regulation of self-renewal and programmed cell death and differentiation of squamous epithelia [@bb0070], [@bb0075]. These observations raise the question whether these TP53 homologues that control physiological epithelial self-renewal and differentiation may also be dysregulated by CK2 to unleash the expression of stem cell genes and phenotype in cancer.

We recently showed that HNSCC with mtTP53 often retain and overexpress related family member, TAp73, which has the potential to replace TP53 function [@bb0080]. TAp73 has an N-terminal transactivation (TA) domain which shares homology, transactivating, and tumor suppressor function with TP53. In HNSCC with mtTP53, our studies revealed that TAp73 is capable of repressing expression of key TP53 target growth arrest and apoptotic genes including *p21*, *NOXA* and *PUMA*. However, although overexpressed, TAp73 is inactivated by a reversible mechanism involving inflammatory signaling and displacement from p53 promoter response elements by ΔNp63α, a p63 isoform lacking the full N-terminal TA domain. Whether and how CK2 signaling may contribute to TAp73 inactivation, and CSC gene expression and phenotype, is unknown, but could provide a potential mechanism to target for prevention of malignant progression in cells after mutation of TP53.

In the present study, we noted from gene expression profiling that *Sox2*, *Oct4* and *Nanog* gene expression is increased in HNSCC lines in which TAp73 was increased but inactivated, and in the side population previously demonstrated to contain CSC [@bb0030]. Thus, we hypothesized that CK2 signaling may inactivate TAp73 to promote CSC gene expression and phenotype in HNSCC with mtTP53. Here, we examined whether CK2 mediates inactivation of TAp73, to orchestrate expression of key CSC-related transcription factor genes *Nanog*, *Sox2* and *Oct4*, the side population, clonogenic survival, and sphere forming CSC phenotypes in HNSCC expressing TAp73 with mtTP53.

Materials and Methods {#s0010}
=====================

Cell Lines {#s0025}
----------

The UM-SCC cell lines were obtained from Dr. Thomas E. Carey, University of Michigan, and re-genotyped and origin confirmed in 2010 [@bb0085]. Genotyped stocks were frozen and used within 3 months of thawing. Expression of TP53, p63, and p73 isoforms and TP53 sequence for exons 4 to 9 was confirmed in our laboratory as previously reported [@bb0080], [@bb0090]. Primary human epidermal keratinocytes (HEKA) or Oral Keratinocytes (HOK) were cultured in accordance with the supplier\'s protocol (Invitrogen) and used within 5 passages.

Reagents, siRNA and Plasmid Transfection {#s0030}
----------------------------------------

CK2 inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) was from Calbiochem and used as described previously [@bb0055]. CX-4945 is a novel selective CK2 inhibitor [@bb0095] obtained from Cylene Pharmaceuticals under a Materials Transfer Agreement with NIDCD. The oligonucleotide sequences for TAp73 specific siRNA inhibition were: 5′r(CGGAUUCCAGCAUGGACGU)d(TT)3′and 5′r(ACGUCCAUGCUGGAAUCCG).

d(TT)3′ (Integrated DNA Technologies, IDT). The CK2 specific siRNAs were from Dharmacon/Thermo Scientific, CK2A1, siGENOME SMARTpool (Cat\# M-003475-03); CK2A2 ON-TARGET plus SMARTpool (Cat\# L-004752-00); CK2B, ON-TARGETplus SMARTpool (Cat\# L-007679-00); Control siRNA, ON-TARGET*plus* Non-targeting Pool (Cat\# D-001810-10-05). The p53/p73 specific response element pG13-luc, PUMA-luc, and p21/WAF1-luc luciferase reporter genes were kindly provided by Dr. Alex Zaika, Vanderbilt University [@bb0100]. The expression vector containing a human Flag-pcDNA3-TAp73 was kindly provided by Dr. Zhi-Min Yuan, Harvard University [@bb0105]. The TAp73-T27A mutant, in which Thr-27 was substituted to Ala (T27A), was synthesized by GENEWIZ, Inc, and sequence verified. All transfections were performed using Lipofectamine 2000 according to the manufacturer\'s instructions (Invitrogen/Life Technology). Each sample was assayed in triplicate and data were presented as mean ± SD.

Western Blot and Coimmunopreciptiations {#s0035}
---------------------------------------

Western blot analysis and co-immunoprecipitation was performed as previously [@bb0080] with antibodies indicated, CK2α (Santa Cruz, sc-6479), CK2α′ (Santa Cruz, sc-6481), Nanog (Cell Signaling, 4903), Oct4 (Cell Signaling, 4286), Sox2 (Cell Signaling, 2748), beta-actin (Cell Signaling, 4967), TAp73 (IMGENEX,IMG-246), p73 (IMGENEX,IMG-259A), Oct-1 (Santa Cruz, sc-53830), Flag antibody(Sigma, M2), PUMA (Cell Signaling, 4976).

Real time RT-PCR {#s0040}
----------------

RNA isolation and cDNA synthesis were performed as previously [@bb0080]. PCR primers for TAp73(GGCTGCGACGGCTGCAGAGC; GCTCAGCAGATTGAACTGGGCCAT)were synthesized by Invitrogen, and other primers used were purchased (Applied Biosystems). Amplification conditions were: 2 minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C, carried out using an ABI Prism 7700 Sequence Detection System (Applied Biosystems). Relative gene expression values were calculated after normalization to 18S rRNA.

Flow cytometric analysis {#s0045}
------------------------

Flow cytometric assay for SP cells in HNSCC was adapted from Tabor et al. [@bb0030]. We cultured the lines with control diluent culture medium, DMAT, CX-4945 and/or transfected them with different siRNAs where indicated. Both floating and adherent cells detached using trypsin-EDTA (In vitrogen) were collected, centrifuged, washed and resuspended in DMEM containing 2% FCS (staining medium) and preincubated in a 1.5-ml Eppendorf tube at 37°C for 10 minutes. Cells were labeled in the same medium at 37°C for 90 minutes with 2.5 μg/ml Hoechst 33342 dye (Sigma-Aldrich, St. Louis, MO), either alone or in combination with 50 mM verapamil (Sigma-Aldrich), as negative control. Cells were centrifuged and resuspended in cold DMEM and filtered through 40 μm mesh. Propidium iodine (BD Biosciences, San Diego, CA) was added at 2 μg/ml for detection of dead cells. Cells were washed twice with cold PBS, then fixed with cold 70% ethanol and kept overnight at 4°C. Then, 3 to 5 × 10^4^ cells were analyzed by a FACSVantage fluorescence-activated cell sorter (BD Biosciences) using dual-wavelength analysis (blue, 424 nm; red, 630 nm) after excitation with 350-nm UV light. Propidium iodide-positive dead cells (\< 15%) were excluded from the analysis.

*In vitro* kinase assays {#s0050}
------------------------

The Flag-cDNA3-TAp73 and Flag-cDNA3-TAp73-T27A fusion proteins were expressed in UM-SCC-46 cells and immobilized on anti-Flag-agarose beads. Anti-Flag-agarose beads were incubated with 10 mg of protein lysates of UM-SCC-46 cell 48°C for 2 hours, then washed three times with buffer (20 mM Tris--HCl at pH 7.5, 200 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton X-100, 0.1 mM dithiothreitol, 1 mM PMSF protease inhibitor). The samples were then incubated in 400 ml buffer (100 mM Tris, pH 8.0 20 mM MgCl2, 100 mM NaCl, 50 mM KCl and 100 mM ATP containing 5 μCi of γ-\[^32^P\]-ATP) with 300 U recombinant CK2 (α2β2, New England Biolabs, P6010S) at 30°C for 30 minutes. The kinase reactions were terminated by washing the samples twice and re-suspending the samples in SDS sample buffer. The samples were boiled for 5 minutes and the proteins resolved by SDS-PAGE. Phosphorylation of Flag-TAp73 was assessed by SDS-PAGE and autoradiography of the dried gels. Loading of the recombination TAp73 protein was compared by Coomassie BlueTM-stained SDS-polyacrylamide gels.

Identification of CK2 motif in TAp73 {#s0055}
------------------------------------

CK2 phosphorylation sites on TAp73 were predicted using Scansite. T27 was identified as a CK2 phorphorylation site on the human TAp73 gene. Coincidence with human T27, a similar CK2 phosphorylation site T31 was predicted on mouse TAp73 gene using the Scansite program.

Clonogenic Assay {#s0060}
----------------

Human UM-SCC-1 and UM-SCC-46 were plated as 200cell/well in 6-well plates. Each cell line was plated in triplicate and incubated for 4 hours in CO~2~ incubator at 37°C to allow cells attach to the dish. Then cells were immediately treated with 0.5, 1 and 5 μM CK2 inhibitor CX4945 with DMSO as negative control. The culture medium is same as for sphere formation assay, below. After 14 days the cells were washed, fixed and stained with 0.5% crystal violet. The colonies with ≥ 50 cells were counted.

Sphere formation assay {#s0065}
----------------------

Human UM-SCC-1 and UM-SCC-46 cells were plated as 500cell/well in 6-well ultra-low adherent dish and treated with 0.5, 1 and 5 μM CK2 inhibitor CX4945 with DMSO as negative control. The culture medium is modified as serum free Keratinocyte-SFM medium (GIBCO) containing EGF (10 ng/ml) (StemCell) and FGF (5 ng/ml) (StemCell). Spheres ≥ 50 μm were counted under the microscopy after 14 days. SCC13 cells form monolayer colonies instead of sphere and only colonies with ≥ 100 cells were counted.

Results {#s0015}
=======

Expression of CSC-related markers is increased in a HNSCC subset overexpressing inactivated TAp73 and mtTP53, and their CSC-like side population {#s0070}
------------------------------------------------------------------------------------------------------------------------------------------------

Nanog, Oct4 and Sox2 are established stem cell markers, for which expression has been studied in only a limited number of HNSCC lines, and the mechanism(s) regulating their overexpression has not been fully determined [@bb0035]. We surveyed expression of these CSC markers in a panel of 9 UM-SCC lines. We observed increased mRNA and/or protein levels of these CSC markers in a subset of cell lines compared with human epidermal keratinocytes (HEKA) or oral keratinocytes (HOK) as controls ([Figure 1](#f0005){ref-type="fig"}*A* and B). Interestingly, Nanog, Oct4 and Sox2 protein expression was increased in four cell lines (UM-SCC-22A, -B, -38, and -46), we previously found to exhibit increased expression but attenuated function of tumor suppressor TAp73 and mtTP53 [@bb0080]. Higher relative mRNA expression of *Sox2* detected by qRT-PCR in UM-SCC-22A, -22B, -38, -46 cells was due to low signal in control HEKA. The results were verified in independent experiments, and consistent with low Sox2 protein in control cells in [Figure 1](#f0005){ref-type="fig"}*B* by Western blot.Figure 1A subset of HNSCC cell lines and side population (SP) cells exhibit increased expression of CSC-related markers. A. Basal mRNA levels for *Nanog*, *Oct4*, and *Sox2* were quantified by qRT-PCR in HEKA and nine UM-SCC cell lines, including 3 lines with deficient expression of wt TP 53 (UM-SCC-1, -6, -9), 2 lines lacking mtTP53 (UM-SCC-11A, -11B) and 4 lines overexpressing TAp73 with mt TP53 (UM-SCC-22A, -22B, -38 and -46)(16). Higher relative expression of *Sox2* in UM-SCC was due to low signal in control HEKA, verified in an independent experiment and consistent with low Sox2 protein in control in panel B by Western blot. B. Basal expression of Nanog, Oct4, and Sox2 proteins was analyzed by Western blot in whole cell lysates of control HOK and 9 UM-SCC cell lines, with β-actin used as control for loading. C. UM-SCC-46 cell lines were labeled with Hoechst 33342 dye and analyzed by flow cytometry without and with treatment with verapamil. Hoechst^Low^ SP cells highlighted within the window indicated are quantified. D. The mRNA expression of CSC related gene markers *Nanog*, *Oct4*, *Sox2*, *BMI1*, *ABCG2*, and pro-apoptotic gene *PUMA* were assessed in non-SP and SP sub-populations sorted by FACS, using QRT-PCR. The expression level in non-SP cells is normalized to 1.0. Columns, mean between triplicate samples; bars, SD. \*, Student *t* test, *P* \< .05.

The side population (SP), which exhibits low Hoechst dye 33342 uptake by UV fluorescence activated cell sorter (FACS) analysis, has previously been shown to be enriched for CSC markers, anchorage independent sphere formation, and tumorigenic capacity in a variety of cancers, including HNSCC [@bb0030]. We identified the SP in UM-SCC-46 from the subset expressing the CSC markers with TAp73 and mtTP53 ([Figure 1](#f0005){ref-type="fig"}*C*). The SP gated in UM-SCC-46 was significantly reduced by treatment with verapamil, a blocker of calcium-dependent Hoechst dye exclusion, previously shown to be a feature of the SP containing CSC in HNSCC and other cancers that express ABC transporters [@bb0030]. The SP displayed significantly increased expression of *Nanog*, *Oct4*, and *Sox2* ([Figure 1](#f0005){ref-type="fig"}*D*), which are key transcription factors implicated in epithelial SP and CSC [@bb0005], [@bb0010], [@bb0035]. Further, we confirmed that the SP isolated by FACS exhibited significantly increased expression of mRNA for independent CSC markers *BMI-1*, and transporter *ABCG2*, compared with non-SP cells ([Figure 1](#f0005){ref-type="fig"}*D*, *P* \< .05), as previously reported for HNSCC [@bb0030]. By contrast, expression of pro-apoptotic gene *PUMA*, a TP53/TAp73 target which exhibits reduced expression in HNSCC [@bb0080], was also slightly reduced in SP cells ([Figure 1](#f0005){ref-type="fig"}D, *P* \< .05). Thus, increased expression of multiple established CSC transcription factors and markers is detected in a subset of HNSCC lines, and enriched in the SP of UM-SCC-46, one of the lines with increased expression of inactivated TAp73 with mtTP53.

CK2 inhibitor or siRNA reduce CSC gene and protein expression and the side population {#s0075}
-------------------------------------------------------------------------------------

As we previously observed that inhibition of protein kinase CK2 inhibits HNSCC tumorigenesis [@bb0055], we examined if established CK2 inhibitor (DMAT) or silencing RNAs (siRNA) could inhibit the CSC markers, utilizing two independent cell lines from the subset overexpressing these CSC markers and TAp73. CK2 inhibitor DMAT significantly reduced *Nanog*, *Oct4*, and *Sox2* mRNA expression in both UM-SCC-22A and -46 ([Figure 2](#f0010){ref-type="fig"}*A*). DMAT had corresponding inhibitory effects on expression of these proteins in UM-SCC-46 ([Figure 2](#f0010){ref-type="fig"}*B*), and -22A ([Suppl. Figure 1A](#ec0005){ref-type="supplementary-material"}). Combining siRNAs targeting both CK2α/α′ catalytic subunits inhibited most of the CSC marker mRNAs in the 2 cell lines except Oct4 in UM-SCC-22A ([Figure 2](#f0010){ref-type="fig"}*C*), but did inhibit all three CSC markers at the protein level in UM-SCC-46 ([Figure 2](#f0010){ref-type="fig"}*D*) and -22A ([Suppl. Figure1B](#ec0005){ref-type="supplementary-material"}). The individual CK2α and α′ subunit siRNAs had a variable effect on expression of the different CSC marker mRNA and proteins ([Figure 2](#f0010){ref-type="fig"}, *C* and *D*, [Suppl. Figure 1, A and B](#ec0005){ref-type="supplementary-material"}), similar to that observed previously for multiple genes in other cell lines [@bb0055]. Corresponding to the effects of DMAT on the CSC markers, is a marked reduction in SP cells ([Figure 2](#f0010){ref-type="fig"}*E*). Normalized to control (0.97 = 100%), DMAT decreased SP by 65% and 96% at 10 and 20 μM, respectively ([Figure 2](#f0010){ref-type="fig"}*E*). Similarly, siRNA targeting both CK2α/α′ catalytic subunits potently reduced the SP, when compared with transfection with scrambled control siRNA ([Figure 2](#f0010){ref-type="fig"}*F*). These inhibitory effects of CK2 inhibitor DMAT or siRNA suggest that CK2 may be important in regulation of CSC genes and the side population phenotype in HNSCC.Figure 2CK2 inhibition by DMAT or CK2α/α′ siRNA suppresses CSC-related SP cells and markers in two independent HNSCC lines. A. CK2 inhibitor DMAT attenuates CSC marker gene *Nanog*, *Oct4*, *and Sox2* mRNA expression in UM-SCC-22A (*Upper panel*) and UM-SCC-46 (*Lower panel*). Quantitation of target genes was assessed using QRT-PCR with the treatment of increasing concentration of DMAT. Bars, SD. \*Reduced versus non-treated, student t test, *P* \< .05. B. Western blot showing Nanog, Oct4, and Sox2 protein expression are decreased in whole cell extracts from UM-SCC-46 48 hours after treatment with increasing concentrations of DMAT. β-Actin was used as loading control. Similar results for UM-SCC-22A are shown in Suppl Figure 1A. C. Effect of individual and combined CK2α and α′ siRNA knockdown on CSC marker *Nanog*, *Oct4*, *and Sox2* mRNA expression in UM-SCC-22A (*Upper panel*) and UM-SCC-46 (*Lower panel*). The expression level in control siRNA-treated sample is normalized to 1.0. Columns, mean between triplicate samples; bars, SD. \*Student *t* test, *P* \< 0.05. D. Effect of individual and combined CK2α and α′ siRNA knockdown on CSC marker protein expression in UM-SCC-46, 48 hours after transfection with siRNA of CK2α, CK2α′, CK2α + α′, and scramble siRNA control. Nanog, Sox2, Oct4, CK2α, CK2α′ were detected, with β-actin used as loading control. Similar results for UM-SCC-22A are shown in Suppl Figure 1B. E. CK2 inhibitor DMAT and F. CK2α/α′ siRNAs inhibit SP cell detection in HNSCC. UM-SCC-46 cells pre-treated with 10 or 20 μM DMAT or DMSO diluent containing medium alone, or 100 nM scrambled control or CK2α/α′ siRNAs were labeled with Hoechst 33342 dye, and analyzed by flow cytometry. The percent Hoechst^Low^ SP cells highlighted within the window indicated were reduced by CK2 inhibitors.

CK2 inhibitor and siRNA increase expression and function of TP53 family member TAp73 which acts as a suppressor of CSC genes and the side population {#s0080}
----------------------------------------------------------------------------------------------------------------------------------------------------

We previously observed that CK2α suppresses TP53 and TAp63 family member gene expression [@bb0055]. Thus, we explored if CK2α modulates the homologous TAp73 tumor suppressor isoform, and whether CSC gene signatures and the SP cell phenotype are regulated by a mechanism involving TAp73. CK2 inhibition by DMAT or CK2α siRNA similarly enhanced expression of TAp73 mRNA in UM-SCC-46 ([Figure 3](#f0015){ref-type="fig"}*A*), supporting a role for CK2α in repression of TAp73 gene expression. DMAT also increased TAp73 but not faster migrating ΔNp73 isoforms as detected by TAp73 or p73 antibodies when compared to constitutive Oct1 as a loading control in nuclear extracts ([Figure 3](#f0015){ref-type="fig"}*B*), a requisite for possible tumor suppressor function in gene regulation. Conversely, TAp73 siRNA knockdown resulted in dose dependent enhancement of *Oct4* and *Nanog* mRNA expression ([Figure 3](#f0015){ref-type="fig"}*C*). TAp73 siRNA knockdown in UM-SCC-22A cells enhanced *Sox2* mRNA expression ([Suppl. Figure 2A](#ec0010){ref-type="supplementary-material"}), but not in UM-SCC-46 cells ([Suppl. Figure 2B](#ec0010){ref-type="supplementary-material"}). Furthermore, a decrease of Sox2, Oct4 and Nanog protein expression with CK2 inhibitor DMAT treatment was attenuated by TAp73 siRNA knockdown ([Figure 3](#f0015){ref-type="fig"}D). Together, these findings suggest CK2 inhibitor modulation of TAp73 expression and/or function may contribute to repression of these proteins. To further confirm the potential of CK2 inhibition to enhance TAp73 function as a tumor suppressor, we examined the effects of DMAT and CK2α siRNA on classical TP53/TAp73 inducible genes. CK2 inhibition by DMAT or CK2α siRNA had a reciprocal effect, enhancing TAp73 inducible TP53/TAp73 response element specific reporter pG13, as well as growth arrest and apoptotic genes *CDKN2A(p21)*, and *PUMA* ([Suppl Figure 3A, B](#ec0015){ref-type="supplementary-material"}) [@bb0080], [@bb0100]. This effect of CK2 inhibition was also confirmed to be TAp73 dependent, requiring co-expression of TAp73-Flag ([Suppl Figure 3C-E](#ec0015){ref-type="supplementary-material"}), in cell line UM-SCC-1, which is deficient for TAp73 [@bb0080]. Furthermore, DMAT inhibited SP cells, while TAp73 knockdown by siRNA strongly increased the number of SP cells, in the absence or presence of DMAT ([Figure 3](#f0015){ref-type="fig"}E). Together, these results support the hypothesis that CK2-mediated inactivation of TAp73 promotes CSC gene expression and the SP phenotype, while inhibiting growth arrest and apoptotic genes, and that this is reversible by CK2 inhibition.Figure 3CK2 inhibition enhanced TAp73 expression and TAp73 dependent suppression of CSC-related markers and SP cells. A. TAp73 mRNA expression was significantly increased 48 hours after treatment with CK2 inhibitor DMAT (*left*) or transfection with CK2α siRNA (*right*) in UM-SCC46 cells. B. TAp73 and total p73 protein expression was increased in nuclear extracts 48 hours after UM-SCC-46 cells were treated with increasing concentrations of CK2 inhibitor DMAT, as detected by Western blot. Nuclear Oct1 is shown as a constitutive loading control. C. CSC-related *Oct4* and *Nanog* mRNA expression was increased in UM-SCC-46 48 hours after transfection with increasing concentration of 50, 100 and 200 nM TAp73 siRNA. D. CSC-related Sox2, Oct4, and Nanog proteins were decreased 48 hours after DMAT treatment of UM-SCC-46, while TAp73 siRNA knockdown attenuated this effect. E. UM-SCC-46 cells were labeled with Hoechst 33342 dye and analyzed by flow cytometry 48 hours after transfection with control scrambled siRNA or TAp73 siRNA −/+ DMAT. SP cell number decreased after DMAT treatment, while DMAT showed no significant effect on SP cells after TAp73 knockdown.

CK2α interaction with TAp73 is inhibited by DMAT and T27A mutation of a predicted CK2 phospho-acceptor site in the transactivation domain of TAp73 {#s0085}
--------------------------------------------------------------------------------------------------------------------------------------------------

Bioinformatic analysis of TAp73 as a potential substrate for CK2 serine/threonine kinase uncovered a single high probability motif containing threonine at amino acid position 27 (T27) within the transactivation (TA) domain of human TAp73 ([Figure 4](#f0020){ref-type="fig"}*A*; [Suppl Figure 4](#ec0020){ref-type="supplementary-material"}). Supporting the importance of the predicted site, the highly conserved homologous site is found in the TA domain of human (T27) and mouse (T31) in a region of predicted surface accessibility of TAp73 protein ([Suppl Figure 4](#ec0020){ref-type="supplementary-material"}). Reciprocal co-immunoprecipitations established that interaction occurs between CK2α and TAp73, and this interaction is attenuated by CK2 inhibitor DMAT in a dose dependent manner ([Figure 4](#f0020){ref-type="fig"}B). Immunoprecipitation of TAp73 with anti-TAp73, or cells transfected with TAp73-Flag with anti-Flag antibodies, showed enhanced CK2 interaction, whereas this interaction was markedly reduced upon equivalent expression of a sequence-verified T27A point-mutant of TAp73-Flag ([Figure 4](#f0020){ref-type="fig"}, *C* and *E*, top panel). Increased expression of TAp73-Flag was accompanied by increased phosphorylation, while equivalent overexpression of TAp73 with T27A point mutation of the predicted CK2 phosphoacceptor site showed markedly reduced phosphorylation when cell lysates were incubated with recombinant CK2α2β2 in an *in vitro* kinase assay ([Figure 4](#f0020){ref-type="fig"}, *D* and *E*, top panel). These results reveal that CK2α-TAp73 interaction and phosphorylation of TAp73 is inhibited by DMAT or T27A mutation of a predicted CK2 phosphoacceptor site in the transactivation domain of TAp73.Figure 4CK2 and TAp73 interaction is inhibited by CK2 inhibitor DMAT or T27A point mutation within a predicted CK2 phospho-acceptor motif in TAp73. A. CK2 interaction with TAp73 is predicted by presence of a high probability CK2 phosphorylation site at Threonine 27 (T27) within the TA domain of human TAp73 using Motifscan (Suppl Figure 4). B. Immunoprecipitation (IP) with anti-CK2α or TAp73 antibodies demonstrates reciprocal interaction between CK2α and TAp73 on immunoblotting (IB) in whole cell lysates of UM-SCC-46 cells. The interaction is decreased after treatment with increasing amount of CK2 specific inhibitor DMAT (10, 20 μM). C. Interaction between CK2α and TAp73 is decreased 48 hours after transfection with Flag-T27A-TAp73 mutant when compared with Flag-TAp73 control. Whole cell lysates from UM-SCC-46 cells were immunoprecipitated (IP) with TAp73 or Flag antibodies, and then immunoblotted (IB) with CK2α antibody. Physical interaction between CK2α and TAp73 was increased after over-expression of wild type TAp73, but decreased between Flag-T27A and CK2α. D. *In vitro* kinase assay shows decreased phosphorylation of TAp73 after T27A mutation. Lysates from cells transfected with empty vector, Flag-TAp73, or Flag-T27A were incubated with the recombinant CK2α2β2 protein in the presence of \[γ-32P\]ATP. The reaction mixtures were separated by SDS-PAGE and subjected to autoradiography (top panel). Bottom panel shows the Coomassie Brilliant Blue staining of the Flag-TAp73 fusion proteins as the loading control. E. Top panel, equivalent expression of Flag-TAp73 and Flag-T27A TAp73 in lysates used for C, D, E, obtained 48 hours after UM-SCC-46 cells were transfected with empty vector, wild type TAp73, or T27A mutant form of TAp73; lower panels, T27A TAp73 enhances inhibition of CSC markers and expression of proapoptotic protein PUMA. The protein expression of TAp73, Nanog, Sox2 and PUMA in whole cell lysates were assessed by Western blot, with β-actin as the loading control.

Mutation of the predicted CK2 T27A phosphoacceptor site enhances TAp73 inhibition of CSC marker expression and SP cells {#s0090}
-----------------------------------------------------------------------------------------------------------------------

Overexpression of TAp73, which exhibited increased CK2 interaction and phosphorylation ([Figure 4](#f0020){ref-type="fig"}, *C* and *D*), resulted in only slight inhibition of CSC markers Nanog and Sox2, or reciprocal enhancement of TAp73-inducible proapototic protein PUMA ([Figure 4](#f0020){ref-type="fig"}*E*). However, similar expression of the CK2 phospho-acceptor mutant T27A-TAp73 that exhibited reduced interaction and phosphorylation ([Figure 4](#f0020){ref-type="fig"}*C* and *D*), strongly repressed the CSC markers, and reciprocally enhanced TAp73 inducible proapoptotic protein PUMA ([Figure 4](#f0020){ref-type="fig"}*E*). Consistent with these effects, overexpression of TAp73 only partially reduced SP cells, while T27A-TAp73 strongly reduced SP cells detected ([Figure 5](#f0025){ref-type="fig"}*A*). Treatment with CK2 inhibitor DMAT resulted in inhibition of SP cells detected in empty vector control and TAp73 transfected cells, but had little additional effect after near complete SP inhibition observed with overexpression of T27A-TAp73 ([Figure 5](#f0025){ref-type="fig"}*B*). These data support that pharmacologic CK2 inhibition or prevention of T27 phosphorylation by T27A mutation enhances the repressive effect of TAp73 on these CSC markers and SP cells.Figure 5TAp73-T27A mutation of CK2 phosphoacceptor site and CK2 inhibitor DMAT suppress CSC SP cells. 48 hours after transfection with empty vector control, Flag-TAp73, or Flag-T27A TAp73, UM-SCC-46 cells were labeled with Hoechst 33342 dye and analyzed by flow cytometry. A. Without treatment. B. Treatment with DMAT 20 μM. UM-SCC-46 cells were examined for Hoechst dye uptake. Hoechst^Low^ SP cells are highlighted, and % total cells are shown.

CK2 promotes clonogenic survival and CSC spheres {#s0095}
------------------------------------------------

To further examine if CK2 regulates CSC phenotypes, we investigated its role in clonogenic colony and tumor spheroid formation, two CSC features previously shown to correspond to SP and enhanced tumorigenicity in HNSCC (6). We used a novel selective CK2 inhibitor, CX4945, currently under investigation in clinical trials [@bb0095]. CK2 inhibitor CX-4945 significantly reduced clonogenic survival ([Figure 6](#f0030){ref-type="fig"}*A*) and sphere formation ([Figure 6](#f0030){ref-type="fig"}*B*) in UM-SCC-1 and -46, in a dose dependent manner (\**P* \< .05). The morphologic effects of CK2 inhibitor on colony ([Figure 6](#f0030){ref-type="fig"}*C*) and sphere formation ([Figure 6](#f0030){ref-type="fig"}*D*) are linked with the SP CSC phenotype [@bb0025]. Together, these data indicate the potential of CK2 inhibition to inhibit SP, clonogenic and sphere phenotypic features, that are characteristic of CSC in HNSCC [@bb0025].Figure 6Pharmacological CK2 inhibitor CX-4945 inhibits clonogenic survival and sphere formation by HNSCC. CK2 inhibitor CX4945 inhibits clonogenic survival (A) and sphere formation (B) of UM-SCC-1 and UM-SCC-46 lines in a dose dependent manner between 0.5 to 5 μM in 3 replicate experiments. \*Students *t* test, *P* \< .05. C. Photomicrographs showing CX-4945 inhibition of colony formation in UM-SCC-46. D. Photomicrographs showing CX-4945 inhibition of tumor sphere formation in UM-SCC-1 and -46.

Discussion {#s0020}
==========

Here, we unveil a new mechanism by which kinase CK2-mediated TAp73 phosphorylation and inactivation, enables enhanced expression of stem cell genes *Nanog*, *Sox2*, *Oct4* and phenotypes that are implicated in CSC of HNSCC and other cancers ([Figure 7](#f0035){ref-type="fig"}) [@bb0005], [@bb0035]. Recent data available from The Cancer Genome Atlas provides evidence for amplification of *Sox2*, *Oct4* and/or *Nanog* genes in over 20% of tumors, indicating that these genes may also be deregulated by direct genomic alterations in HNSCC [@bb0065], [@bb0110]. Unexpectedly, we observed that expression of these CSC transcription factors is increased in a subset of HNSCC lines with increased expression of inactivated TAp73 and mtTP53 [@bb0080]. Pharmacologic or siRNA inhibition of CK2 further enhanced TAp73 expression. CK2 inhibition or mutational inactivation of a predicted CK2 phospho-acceptor motif in the transactivation domain of TAp73 then restored p73 function, repressing mRNA and protein expression of these CSC transcription factor genes ([Figure 7](#f0035){ref-type="fig"}). Conversely, we found CK2 inhibition reciprocally induced TAp73-inducible growth arrest and proapoptotic genes *CDKN2A(p21)* and *PUMA* in HNSCC \[[@bb0080]; [Suppl Figure 1](#ec0005){ref-type="supplementary-material"}\], indicating a pivotal role as a switch regulating genes that determine cell fate. Concordantly, CK2 inhibition attenuated the SP subset, clonogenicity, and sphere formation, linked to CSC phenotype and tumorgenicity in HNSCC and other cancers [@bb0030].Figure 7Model of the role of CK2 phosphorylation and inhibition of TAp73 in CSC gene program and phenotype. CK2 theonine/serine kinase mediates phosphorylation and inactivation of tumor suppressor TAp73, promoting expression of CSC genes and phenotype. CK2 inhibition by small molecule inhibitors DMAT or CX-4945, or T27A mutation of the CK2 phosphoacceptor motif of TAp73 uncovers TAp73 as a suppressor of CSC genes and phenotype.

We found that CK2 inhibition enhanced TAp73 expression and dependent repression of several known CSC transcription factor genes in two independent lines from an HNSCC subset overexpressing TAp73 with mtTP53. We recently demonstrated that CK2 similarly contributes to repression of TP53 and TAp63 mRNA and protein in a subset of HNSCC with wtTP53 genotype, an effect also reversible by CK2 inhibition [@bb0055]. Together, our current and prior studies indicate an important role of CK2 in pan-repression of expression and function of tumor suppressor TP53 and isoforms TAp63, and TAp73 in HNSCC subsets with wt or mtTP53. With the prevalence of TP53 mutation or inactivation in nearly all HNSCC [@bb0065], identification of key kinases reversibly regulating TAp73 inactivation is of potential biologic and therapeutic importance. Because TAp73 is rarely mutated and may function as a tumor suppressor in place of TP53 [@bb0075], [@bb0080], druggable kinase targets such as CK2 capable of reactivating TAp73 have potential for prevention or therapy.

CK2α/α′ kinase subunits are reported to be overexpressed and form nuclear complexes associated with chromatin in HNSCC and other cancers [@bb0040], [@bb0050], but their nuclear function was heretofore obscure. Previously, we observed predominantly nuclear localization of both CK2α/α′ catalytic subunits and TAp73 in HNSCC [@bb0055], [@bb0080]. We establish here that nuclear CK2 and TAp73 interact by co-IP, and this interaction is blocked by CK2 inhibitor DMAT, supporting their role in a common mechanism reversible by CK2 inhibitors. The effect of CK2 inhibitor in suppressing CSC target protein expression and SP phenotype was abrogated by TAp73 siRNA. Conversely, CK2 inhibition enhanced expression of growth arrest and pro-apoptotic genes *CDKN2A(p21)* and *PUMA* required TAp73, together supporting their dependence on the tumor suppressor function of TAp73. Further defining the nature of this interaction, we identified a threonine site (T27) within a single high probability and conserved CK2 motif within the N-terminal domain critical for CK2 interaction and transactivation function of TAp73. T27A substitution of this site attenuated CK2-TAp73 interaction, TAp73 phosphorylation, reciprocal expression of CSC marker and PUMA proteins, and the SP phenotype. CK2 inhibitor CX-4945, which is currently in clinical trials, also inhibited SCC cell clonogenicity and sphere formation *in vitro*. Examination of effects of CK2α/α′ inhibition delivered by nanoparticles in specimens from our previous study further indicated that CK2 inhibition can inhibit tumor growth, and enhance p73 expression in tumor *in vivo* \[[@bb0055], Y. Bian and C. Van Waes, unpublished observations\]. Together, these studies implicate CK2-TAp73 interaction and T27 phosphorylation as a molecular switch that promotes cancer stem cell genes, side population, and phenotype.

A novel finding of this study is the identification of a conserved CK2 T27 phospho-acceptor site in the transactivation domain of human and murine TAp73, which is important in regulating the functional activity of TAp73. T27 was also reported as a functional inhibitory phosphorylation site for Polo-like Kinase-1 (Plk1) \[[@bb0115], [@bb0120]\], another key regulator promoting cell cycle progression and survival [@bb0125]. Interestingly, the TA domain of TP53 lacks this motif, but contains a different T18 motif phosphorylated by kinases ATM/ATR, that stabilize its expression and function, to promote growth arrest and apoptosis in DNA damage responses [@bb0130]. Thus, while TP53 and TAp73 can both function to suppress growth, the contrasting functions of ATR/ATM and CK2 and respective phosphorylation sites in TP53 and TAp73 proteins could underlie the important functional differences in their evolutionary roles in regulating growth arrest or promotion in damaged and replicating epithelia.

Here we reveal that CK2 inhibition and TAp73 activation mediates repression of Nanog, Oct4 and Sox2 mRNA and protein expression, and CSC SP phenotype, while promoting expression of known TAp73 inducible growth arrest and proapoptotic genes such as *p21WAF1* and *PUMA* [@bb0070], [@bb0075], [@bb0080]. TP53 was previously implicated in binding the promoter and repressing Nanog mRNA and protein expression, and promoting differentiation of embryonic stem cells in response to DNA damage [@bb0060]. Recently, overexpression of the ΔNp73 isoform, lacking the N-terminal region and full transactivating domain, was also shown to enhance Sox2, Oct4 expression and generation of human induced pluripotent stem cells [@bb0135], supporting a broader overlap in function of TP53 and TAp73 in repressing these stem cell genes. Preliminary analysis of the promoters of Oct4, Nanog, and Sox2 reveal that they contain predicted sites for TP53/TAp73 and other transcription factors, but it is also possible that TAp73 regulated intermediary transcription factors or microRNAs co-modulate CSC genes.

Prior studies suggest that CK2 may modulate the CSC phenotype through a variety of transcriptional mechanisms. A recent study demonstrates that CK2α is associated with Hedgehog (Hh)-Gli1 and Notch1 pathway transcription factors in lung cancers, where knockdown of CK2α reduced Hh/Gli1 and Notch1 signaling and the stem-like side population [@bb0140], [@bb0145]. Knockout of the regulatory CK2β subunit in mice inhibited transcription factor Olig2, embryonic neural stem cell proliferation, and oligodendrocyte development [@bb0150]. Increased CK2α relative to CK2β is linked to upregulation of *SNAIL1*, *TWIST1*, *ZEB1/2*, and epithelial mesenchymal transition of breast cancer cells [@bb0155]. These observations suggest CK2 can enhance multiple pathways important in CSC. Although it is not yet known if TAp73 directly or indirectly regulates CSC genes, preliminary chromatin immunoprecipitation sequence analysis of the promoters of Oct4, Nanog, and Sox2 reveal that they contain sites for TAp73 binding (H Cheng and C Van Waes, unpublished observations). Future chromatin immunoprecipitation sequencing studies for CK2α, TAp73 and other transcription factors in promoter regulation of these genes may enhance understanding of the mechanisms and potential targets involved in orchestrating this stem cell gene program.

Here, we find that small molecule CK2 inhibitors DMAT or CX-4945 enhance TAp73 expression and function, and inhibit SP and CSC phenotypes in HNSCC with mtTP53 *in vitro*. Interestingly, CK2 inhibition was shown to inhibit PI3K/Akt axis signaling via Akt serine 129 [@bb0105] and induce TAp73 (this study), similar to that observed with a selective PI3K-mTOR inhibitor in our recent study [@bb0160]. Studies by others show that mTOR inhibitor rapamycin also potentiates TAp73 expression, modulates TAp73 dependent p21 expression and growth inhibition *in vitro*, and stem cell related gene signatures linked to prognosis in rhabdomysarcoma [@bb0165], [@bb0170]. These observations suggest CK2 and PI3K/mTOR/Akt axis signaling as well as CK2 phosphorylation of TAp73 may contribute to repression of TAp73 expression and function. We have demonstrated that potent inhibition of CK2 by antisense nanoparticles [@bb0055], or PI3K-mTOR inhibitor [@bb0160] can inhibit tumorigenesis of HNSCC *in vivo*. However preliminary preclinical murine xenograft studies with CK2 inhibitor CX-4945, demonstrate relatively limited inhibitory effects on established tumors *in vivo*, when compared with CX-4945 *in vitro*, where higher concentrations may be achievable. Ongoing studies suggest that inhibition of CK2 or PI3K-mTOR together with other prosurvival signal pathways involved in resistance may enhance the effects on tumor growth and survival. Thus, CK2 and other inhibitors that enhance reactivation of wtTP53 and/or TAp73 function merit further investigation for prevention and therapy of SCC.

The following are the supplementary data related to this article.Supplemental Figure S1.CK2 inhibition by DMAT or CK2α/α′ siRNA suppresses CSC-related SP cells and markers in UM-SCC-22A. A. Western blot showing Nanog, Oct4, and Sox2 protein expression are decreased in whole cell extracts from UM-SCC-46 48h after treatment with increasing concentrations of DMAT. β-actin was used as loading control. B. Effect of individual and combined CK2α and α′ siRNA knockdown on CSC marker protein expression in UM-SCC-22A, 48h after transfection with siRNA of CK2α, CK2α′, CK2α+α′, and scramble siRNA control. Nanog, Sox2, Oct4, CK2α, CK2α′ were detected, with β-actin used as loading control.Supplemental Figure S2.*TAp73* and CSC-related *Nanog*, and *Sox2* mRNA expression 48 hours after transfection and knockdown with TAp73 siRNA in. A.UM-SCC-22A and B. UM-SCC-46 cells. Cells were transfected with lipofection reagent alone, or with 100 nM control or TAp73 siRNA as described in methods. Left panels, TAp73 siRNA efficiently repressed TAp73 mRNA in both lines. Middle panels, *Nanog* mRNA expression was increased in both UM-SCC-22A and -46 cells. Right panels, SOX2 mRNA was increased in UM-SCC-22A but not -46 cells. Ctrl vs TAp73, \* p\<0.05.Supplemental Figure S3.CK2 inhibitor DMAT and CK2α siRNA enhancement of TP53/TAp73 response element, p21 and PUMA luciferase reporter activity is TAp73 dependent. A. CK2 inhibitor DMAT or control containing DMSO diluent or B. CK2α or control siRNA were co-transfected with pG13-Luc containing TP53/TAp73 responsive elements, or p21-Luc or PUMA-luc promoters containing TP53/TAp73 sites in UM-SCC-46,, and luciferase reporter activity was assayed after 48 hours. C. pG13-, p21-, and PUMA-luc were co-transfected without or with Flag-TAp73 and CK2α siRNA in UM-SCC-1 cell which lacks TAp73 and TP53 expression (16), and luciferase activity was assayed after 48 hours. Fold luciferase activity normalized to co-transfected beta-galactosidase reporter is shown.Supplemental Figure S4.*Motif Scan* identifies conserved CK2 Threonine motif at T27 in human and T31 in murine TAp73. The protein query for transcription factor TAp73 is represented schematically as a line, with phosphorylation site predictions for Ser/Thr residues of CK2 (including splice variations) by the Scansite program. A conserved homologous CK2 phosphorylation site was predicted in a region of surface accessibility in human (*Upper panel, T27*) and mouse (*Lower panel, T31*) TAp73 protein.
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